Drug intelligence / Profile preview

RK-03

Development stage: Preclinical
Lead developer: Myopharm
Administration: Oral

Overview

RK-03 is a preclinical-stage therapeutic candidate developed by Myopharm, focusing on anti-inflammatory effects within pancreatic beta cells. It is being investigated for systemic inflammatory indications. The program aims to protect beta cells from inflammatory damage, which is a common factor in the progression of metabolic and autoimmune diseases like diabetes. The specific molecular target and modality of RK-03 have not been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on RK-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RK-03.

Explore the full profile